Literature DB >> 17295394

Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease.

H Randall Griffith1, Jan A den Hollander, Chris C Stewart, William T Evanochko, Steven D Buchthal, Lindy E Harrell, Edward Y Zamrini, John C Brockington, Daniel C Marson.   

Abstract

in vivo (1)H MRS reveals reduced N-acetylaspartate (NAA) and elevated myo-inositol (mI) in patients with mild Alzheimer's disease (AD) and patients with amnestic mild cognitive impairment (MCI). We are unaware of studies that have documented abnormal scyllo-inositol (sI) levels in patients with AD or patients with MCI, although a previous MRS study in older adults has indicated that sI is a peak of interest to measure in AD. Fifteen patients with mild AD, 26 patients with amnestic MCI, and 19 healthy older adults were recruited to this study. All underwent (1)H MRS of the posterior cingulate gyrus of the brain using a 3 T MRI scanner. Increases in the sI/creatine (Cr) ratio were observed in patients with mild AD (P < 0.05). The mI/Cr ratio was raised in patients with mild AD (P < 0.01) and MCI (P < 0.05). Reduced NAA/Cr was detected in patients with mild AD (P < 0.05). The sI/Cr ratio correlated negatively (r = -0.60, P < 0.05) with a measure of clock drawing in patients with mild AD, indicating that impaired cognitive ability in AD is associated with higher concentrations of sI/Cr. In vivo measurement of sI/Cr in the posterior cingulate gyrus of patients with mild AD revealed increases compared with cognitively healthy older adults. Further research on the mechanisms of sI increase in AD is needed. Future studies on the longitudinal course of sI/Cr in MCI and AD appear warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17295394     DOI: 10.1002/nbm.1132

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  12 in total

1.  Combination therapy in a transgenic model of Alzheimer's disease.

Authors:  Bruce G Jenkins; Alpaslan Dedeoglu; Nurgul Aytan; Ji-Kyung Choi; Isabel Carreras; Neil W Kowall
Journal:  Exp Neurol       Date:  2013-10-10       Impact factor: 5.330

Review 2.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

Review 3.  Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain.

Authors:  Linda Chang; Sody M Munsaka; Stephanie Kraft-Terry; Thomas Ernst
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-12       Impact factor: 4.147

4.  Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer's disease mouse models.

Authors:  Ji-Kyung Choi; Isabel Carreras; Alpaslan Dedeoglu; Bruce G Jenkins
Journal:  Neuropharmacology       Date:  2010-04-22       Impact factor: 5.250

Review 5.  Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies.

Authors:  Tao Song; Xiaopeng Song; Chenyawen Zhu; Regan Patrick; Miranda Skurla; Isabella Santangelo; Morgan Green; David Harper; Boyu Ren; Brent P Forester; Dost Öngür; Fei Du
Journal:  Ageing Res Rev       Date:  2021-10-29       Impact factor: 10.895

6.  Neuropsychological function and cerebral metabolites in HIV-infected youth.

Authors:  R Nagarajan; M K Sarma; M A Thomas; L Chang; U Natha; M Wright; J Hayes; K Nielsen-Saines; D E Michalik; J Deville; J A Church; K Mason; T Critton-Mastandrea; S Nazarian; J Jing; M A Keller
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-13       Impact factor: 4.147

7.  Trans-cyclization of phosphatidylinositol catalyzed by phospholipase C from Streptomyces antibioticus.

Authors:  Chuan Bai; Li Zhao; Mario Rebecchi; Ming-Daw Tsai; Karol S Bruzik
Journal:  J Am Chem Soc       Date:  2009-06-24       Impact factor: 15.419

Review 8.  Targeting Abeta and tau in Alzheimer's disease, an early interim report.

Authors:  Todd E Golde; Leonard Petrucelli; Jada Lewis
Journal:  Exp Neurol       Date:  2009-08-27       Impact factor: 5.330

9.  Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.

Authors:  H Randall Griffith; Jan A den Hollander; Ozioma C Okonkwo; Timothy O'Brien; Ray L Watts; Daniel C Marson
Journal:  Alzheimers Dement       Date:  2008-11       Impact factor: 21.566

10.  Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

Authors:  Amer M Burhan; Robert Bartha; Christian Bocti; Michael Borrie; Robert Laforce; Pedro Rosa-Neto; Jean-Paul Soucy
Journal:  Alzheimers Res Ther       Date:  2013-07-08       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.